Peptic ulcer disease (PUD) remains a prevalent gastrointestinal disorder that poses a significant health burden. This article aims to provide an overview of recent advancements and best practices in PUD management.
Novel therapies have emerged, including the use of vonoprazan, a potassium-competitive acid blocker, showing superior efficacy compared to traditional proton pump inhibitors (PPIs). Furthermore, advancements in endoscopic techniques, such as endoscopic submucosal dissection (ESD), provide promising results in treating refractory ulcers.
Empiric PPI therapy remains the first-line treatment, particularly for patients with typical symptoms. Testing and treating for Helicobacter pylori infection is also crucial. For patients with NSAID-associated ulcers, discontinuing NSAIDs and starting PPIs is recommended. If NSAID continuation is necessary, co-therapy with PPIs or the use of COX-2 selective inhibitors should be considered.
Effective patient education is paramount in PUD management. Patients should be advised on the importance of medication compliance, lifestyle modifications, and the avoidance of ulcerogenic substances like NSAIDs and alcohol.
Research is ongoing to develop more effective and safer drugs, and to explore the role of microbiota in PUD. Genetic testing may also offer personalized therapy in the future.
In conclusion, the management of PUD has evolved significantly with the advent of new therapeutic options and the emphasis on patient education. However, the need for further research to enhance our understanding and to develop more effective treatment strategies remains.
1.
NPM1-Mutated AML: Not All Treatments Are Equal
2.
Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey
3.
MRI can save rectal cancer patients from surgery, study suggests
4.
Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer
5.
Rising rates of head and neck cancers in England
1.
A Closer Look at Breast Cancer: Examining the Ultrasound Images
2.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
3.
Molecular Classification of Refractory Anemia: A Comprehensive Review
4.
Ferroptosis-Modulating Therapeutics in Precision Oncology
5.
Blood-Cell Morphology Foundation Models: Transforming Hematological Diagnostics and Clinical Practice
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Thromboprophylaxis In Medical Settings- An Update
3.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
4.
How Platelet Disorders Can Affect the Body
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation